Aeras to support development of TB vaccines

The medical non-profit Aeras and the China National Biotech Group recently signed a memorandum of understanding in order to support the development of tuberculosis vaccines in China and potentially in other parts of the world.

"Aeras is excited to expand our relationship with CNBG," Jim Connolly, president and CEO of Aeras. said. "The synergy created by bringing together CNBG's considerable infrastructure and manufacturing expertise with Aeras' promising TB vaccine pipeline, as well as our clinical and technical expertise, will significantly enhance the likelihood of a new TB vaccine being developed quickly and efficiently."

TB is a major public health concern in China, where more than a million new cases are diagnosed every year. The new partnership is designed to leverage the capabilities of both organizations to develop new vaccines.

The memorandum covers a full spectrum of TB vaccine-related activities, including pre-clinical product development, process development, and manufacturing and clinical development. Details of the specific activities and focus of the collaboration are to be discussed for a future, more definitive agreement.

"At CNBG, we recognize the urgent need to combat tuberculosis and other infectious diseases in both China and around the world," Xiaoming Yang, the president of CNBG, said. "This new collaboration will bring more opportunities to both organizations in pursuing greater innovation and building increased technical capacity for vaccine development."